Kimia Biosciences [KIMIABL] vs Suven Life Sciences [SUVEN] Detailed Stock Comparison
Kimia Biosciences
BSE
Loading...
Suven Life Sciences
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Kimia Biosciences wins in 5 metrics, Suven Life Sciences wins in 6 metrics, with 0 ties. Suven Life Sciences appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Kimia Biosciences | Suven Life Sciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | N/A | -28.31 | N/A |
| Price-to-Book Ratio | 16.79 | 41.36 | Kimia Biosciences |
| Debt-to-Equity Ratio | 394.92 | 0.00 | Suven Life Sciences |
| PEG Ratio | N/A | -0.34 | N/A |
| EV/EBITDA | 10.94 | -24.12 | Suven Life Sciences |
| Profit Margin (TTM) | 7.31% | 84.44% | Suven Life Sciences |
| Operating Margin (TTM) | 6.75% | -2,791.92% | Kimia Biosciences |
| EBITDA Margin (TTM) | 6.75% | N/A | N/A |
| Return on Equity | N/A | -146.15% | N/A |
| Return on Assets (TTM) | N/A | -118.91% | N/A |
| Free Cash Flow (TTM) | N/A | $-1.91B | N/A |
| 1-Year Return | -26.03% | 49.21% | Suven Life Sciences |
| Price-to-Sales Ratio (TTM) | 1.39 | 632.35 | Kimia Biosciences |
| Enterprise Value | $2.06B | $44.90B | Suven Life Sciences |
| EV/Revenue Ratio | 1.72 | 597.31 | Kimia Biosciences |
| Gross Profit Margin (TTM) | N/A | 100.00% | N/A |
| Revenue per Share (TTM) | $26 | $0 | Kimia Biosciences |
| Earnings per Share (Diluted) | N/A | $-8.45 | N/A |
| Beta (Stock Volatility) | 0.97 | 0.78 | Suven Life Sciences |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Kimia Biosciences vs Suven Life Sciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Kimia Biosciences | 1.05% | -0.96% | 1.90% | -46.26% | -6.31% | -17.56% |
| Suven Life Sciences | -2.18% | 3.79% | -10.27% | -21.82% | 76.25% | 63.70% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Kimia Biosciences | -26.03% | -18.52% | 17.43% | 84.95% | 84.95% | 84.95% |
| Suven Life Sciences | 49.21% | 215.69% | 329.98% | -26.12% | 600.33% | 3,806.72% |
News Based Sentiment: Kimia Biosciences vs Suven Life Sciences
Kimia Biosciences
News based Sentiment: NEGATIVE
Kimia Biosciences experienced a significant decline in stock price and financial performance during the month of October 2025. The substantial drops in net sales and profit, combined with a high debt-to-equity ratio, create a concerning picture for investors. The closure of the trading window and AGM proceedings are standard corporate governance but don't offset the negative financial trends.
Suven Life Sciences
News based Sentiment: MIXED
October was a month of conflicting signals for Suven Life Sciences. While the company benefited from a positive pharmaceutical sector rally and maintained a debt-free status, it also reported continued quarterly losses and received a negative analyst rating. This creates a complex investment narrative with both potential opportunities and significant risks.
Performance & Financial Health Analysis: Kimia Biosciences vs Suven Life Sciences
| Metric | KIMIABL | SUVEN |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.75B | ₹47.99B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 5,546 | 184,111 |
| 90 Day Avg. Volume | 12,368 | 150,383 |
| Last Close | ₹37.38 | ₹204.83 |
| 52 Week Range | ₹34.25 - ₹86.85 | ₹102.50 - ₹299.99 |
| % from 52W High | -56.96% | -31.72% |
| All-Time High | ₹86.85 (Jul 02, 2025) | ₹338.50 (Apr 13, 2015) |
| % from All-Time High | -56.96% | -39.49% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.05% | 0.86% |
| Quarterly Earnings Growth | -0.58% | 0.86% |
| Financial Health | ||
| Profit Margin (TTM) | 0.07% | 0.84% |
| Operating Margin (TTM) | 0.07% | -27.92% |
| Return on Equity (TTM) | N/A | -1.46% |
| Debt to Equity (MRQ) | 394.92 | 0.00 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹2.11 | ₹5.04 |
| Cash per Share (MRQ) | ₹0.04 | ₹2.75 |
| Operating Cash Flow (TTM) | ₹0 | ₹-1,590,282,000 |
| Levered Free Cash Flow (TTM) | ₹0 | ₹-1,607,450,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Kimia Biosciences vs Suven Life Sciences
| Metric | KIMIABL | SUVEN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | N/A | -28.31 |
| Forward P/E | N/A | 10.78 |
| PEG Ratio | N/A | -0.34 |
| Price to Sales (TTM) | 1.39 | 632.35 |
| Price to Book (MRQ) | 16.79 | 41.36 |
| Market Capitalization | ||
| Market Capitalization | ₹1.75B | ₹47.99B |
| Enterprise Value | ₹2.06B | ₹44.90B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.72 | 597.31 |
| Enterprise to EBITDA | 10.94 | -24.12 |
| Risk & Other Metrics | ||
| Beta | 0.97 | 0.78 |
| Book Value per Share (MRQ) | ₹2.11 | ₹5.04 |
Financial Statements Comparison: Kimia Biosciences vs Suven Life Sciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | KIMIABL | SUVEN |
|---|---|---|
| Revenue/Sales | N/A | ₹18.67M |
| Cost of Goods Sold | N/A | ₹0 |
| Gross Profit | N/A | ₹18.67M |
| Research & Development | N/A | ₹414.88M |
| Operating Income (EBIT) | N/A | ₹-521.17M |
| EBITDA | N/A | ₹-501.49M |
| Pre-Tax Income | N/A | ₹-515.17M |
| Income Tax | N/A | ₹0 |
| Net Income (Profit) | N/A | ₹-515.17M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | KIMIABL | SUVEN |
|---|---|---|
| Cash & Equivalents | N/A | ₹150.26M |
| Total Current Assets | N/A | ₹754.72M |
| Total Current Liabilities | N/A | ₹234.86M |
| Long-Term Debt | N/A | N/A |
| Total Shareholders Equity | N/A | ₹1.10B |
| Retained Earnings | N/A | ₹-6.01B |
| Property, Plant & Equipment | N/A | ₹756.69M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | KIMIABL | SUVEN |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | KIMIABL | SUVEN |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 5,546 | 184,111 |
| Average Daily Volume (90 Day) | 12,368 | 150,383 |
| Shares Outstanding | 47.31M | 218.07M |
| Float Shares | 3.80M | 67.61M |
| % Held by Insiders | 0.92% | 0.69% |
| % Held by Institutions | 0.00% | 0.02% |
Dividend Analysis & Yield Comparison: Kimia Biosciences vs Suven Life Sciences
| Metric | KIMIABL | SUVEN |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | ₹0.00 |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | ₹0.00 |
| Ex-Dividend Date | N/A | N/A |